SG10201912530XA - Pharmaceutical formulations - Google Patents
Pharmaceutical formulationsInfo
- Publication number
- SG10201912530XA SG10201912530XA SG10201912530XA SG10201912530XA SG10201912530XA SG 10201912530X A SG10201912530X A SG 10201912530XA SG 10201912530X A SG10201912530X A SG 10201912530XA SG 10201912530X A SG10201912530X A SG 10201912530XA SG 10201912530X A SG10201912530X A SG 10201912530XA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical formulations
- formulations
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187102P | 2015-06-30 | 2015-06-30 | |
US201662296524P | 2016-02-17 | 2016-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201912530XA true SG10201912530XA (en) | 2020-02-27 |
Family
ID=56413867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912530XA SG10201912530XA (en) | 2015-06-30 | 2016-06-28 | Pharmaceutical formulations |
Country Status (16)
Country | Link |
---|---|
US (1) | US20170027967A1 (en) |
EP (1) | EP3316869A1 (en) |
JP (2) | JP2018519325A (en) |
KR (2) | KR20180048584A (en) |
CN (1) | CN107921003A (en) |
AU (1) | AU2016285916B9 (en) |
BR (1) | BR112017028140A2 (en) |
CA (1) | CA2921336A1 (en) |
EA (1) | EA201792591A1 (en) |
HK (2) | HK1252156A1 (en) |
IL (1) | IL256491A (en) |
MA (1) | MA42303A (en) |
MX (1) | MX2017016802A (en) |
NZ (1) | NZ738524A (en) |
SG (1) | SG10201912530XA (en) |
WO (1) | WO2017004012A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY35213A (en) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | COMPOUNDS OF THE TYPE OF POLYCYCLIC CARBAMYLPIRIDONS AND THEIR PHARMACEUTICAL USE |
RS62434B1 (en) | 2014-12-26 | 2021-11-30 | Univ Emory | Anti-viral n4-hydroxycytidine derivatives |
JP6621933B2 (en) | 2015-11-09 | 2019-12-18 | ギリアード サイエンシス インコーポレーテッド | Therapeutic composition for treating human immunodeficiency virus |
CA3077624A1 (en) * | 2016-10-01 | 2018-04-05 | James Smeeding | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
TWI820984B (en) * | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | Crystalline forms of tenofovir alafenamide |
KR102626210B1 (en) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
EP3773572A4 (en) * | 2018-03-25 | 2022-01-05 | Biohaven Pharmaceutical Holding Company Ltd. | Rimegepant for cgrp related disorders |
KR102281373B1 (en) | 2018-04-26 | 2021-07-22 | 주식회사 엘지에너지솔루션 | Cathode for solid electrolyte battery and solid electrolyte battery including the same |
KR102016952B1 (en) * | 2019-04-19 | 2019-09-02 | 유니셀랩 주식회사 | The antiviral agent comprising a novel crystalline form and the manufacturing method thereof |
CN114126655A (en) * | 2019-07-03 | 2022-03-01 | 爱尔兰詹森科学公司 | Method of treating HIV in pediatric patients with rilpivirine |
CN117338733B (en) * | 2023-10-12 | 2024-05-28 | 杭州和泽坤元药业有限公司 | Tenofovir disoproxil fumarate tablet and preparation process thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106511357A (en) * | 2010-11-19 | 2017-03-22 | 吉利德科学公司 | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
CN104105484A (en) * | 2012-02-03 | 2014-10-15 | 吉联亚科学公司 | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
WO2015022351A1 (en) * | 2013-08-14 | 2015-02-19 | Ratiopharm Gmbh | Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir |
-
2016
- 2016-02-18 CA CA2921336A patent/CA2921336A1/en not_active Abandoned
- 2016-06-28 EA EA201792591A patent/EA201792591A1/en unknown
- 2016-06-28 AU AU2016285916A patent/AU2016285916B9/en not_active Ceased
- 2016-06-28 BR BR112017028140A patent/BR112017028140A2/en not_active IP Right Cessation
- 2016-06-28 SG SG10201912530XA patent/SG10201912530XA/en unknown
- 2016-06-28 KR KR1020187002383A patent/KR20180048584A/en active Application Filing
- 2016-06-28 CN CN201680045432.1A patent/CN107921003A/en active Pending
- 2016-06-28 NZ NZ738524A patent/NZ738524A/en not_active IP Right Cessation
- 2016-06-28 KR KR1020207009286A patent/KR20200037880A/en active Application Filing
- 2016-06-28 US US15/194,968 patent/US20170027967A1/en not_active Abandoned
- 2016-06-28 WO PCT/US2016/039762 patent/WO2017004012A1/en active Application Filing
- 2016-06-28 MX MX2017016802A patent/MX2017016802A/en unknown
- 2016-06-28 JP JP2017568191A patent/JP2018519325A/en not_active Withdrawn
- 2016-06-28 MA MA042303A patent/MA42303A/en unknown
- 2016-06-28 EP EP16739321.4A patent/EP3316869A1/en not_active Withdrawn
-
2017
- 2017-12-21 IL IL256491A patent/IL256491A/en unknown
-
2018
- 2018-09-07 HK HK18111548.4A patent/HK1252156A1/en unknown
- 2018-10-18 HK HK18113419.6A patent/HK1254343A1/en unknown
-
2019
- 2019-04-30 JP JP2019087062A patent/JP2019116514A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016285916B9 (en) | 2019-04-04 |
AU2016285916A1 (en) | 2018-01-18 |
HK1254343A1 (en) | 2019-07-19 |
US20170027967A1 (en) | 2017-02-02 |
EP3316869A1 (en) | 2018-05-09 |
KR20200037880A (en) | 2020-04-09 |
AU2016285916B2 (en) | 2019-03-07 |
KR20180048584A (en) | 2018-05-10 |
JP2018519325A (en) | 2018-07-19 |
EA201792591A1 (en) | 2018-06-29 |
NZ738524A (en) | 2019-02-22 |
MX2017016802A (en) | 2018-09-06 |
HK1252156A1 (en) | 2019-05-17 |
CA2921336A1 (en) | 2016-12-30 |
MA42303A (en) | 2018-05-09 |
BR112017028140A2 (en) | 2018-08-28 |
CN107921003A (en) | 2018-04-17 |
IL256491A (en) | 2018-02-28 |
JP2019116514A (en) | 2019-07-18 |
WO2017004012A1 (en) | 2017-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL246978A0 (en) | Novel pharmaceutical formulations | |
PL4070787T3 (en) | Pharmaceutical formulations | |
HK1254343A1 (en) | Pharmaceutical formulations | |
ZA201903101B (en) | Pharmaceutical formulations | |
IL262745A (en) | Improved drug formulations | |
HK1245653A1 (en) | Pharmaceutical formulation | |
IL253177A0 (en) | Pharmaceutical formulation | |
ZA201707094B (en) | Pharmaceutical formulations | |
EP3383371C0 (en) | Pharmaceutical formulation | |
EP3337463A4 (en) | Pharmaceutical formulations | |
GB201515310D0 (en) | Pharmaceutical composition | |
HK1245073A1 (en) | Pharmaceutical compositions | |
GB201520862D0 (en) | Pharmaceutical composition | |
GB201506755D0 (en) | Novel pharmaceutical formulation | |
GB201511246D0 (en) | Pharmaceutical formulation | |
IL271908A (en) | Hypercompressed pharmaceutical formulations | |
GB201417589D0 (en) | Pharmaceutical Formulations | |
GB201610440D0 (en) | Pharmaceutical formulations | |
PL3319596T3 (en) | Pharmaceutical compositions | |
GB201521456D0 (en) | Pharmaceutical composition | |
GB201506598D0 (en) | Pharmaceutical compositions | |
GB201507784D0 (en) | Formulations | |
GB201505532D0 (en) | Formulations |